Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

This study has been completed.
Information provided by (Responsible Party):
Cumberland Pharmaceuticals Identifier:
First received: June 8, 2011
Last updated: April 30, 2014
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2014
  Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)